Clinical trial
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent…
NCT00267488 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00267488 |
|---|---|
| Title | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer |
| Official title | An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Endometrial, Endometrial Cancer |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 70 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Dec 21, 2005 |
| Last update posted | Jul 11, 2012 |
| Countries | Canada, Hungary, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: